NasdaqGS - Nasdaq Real Time Price USD
Recursion Pharmaceuticals, Inc. (RXRX)
5.93
+0.56
+(10.45%)
As of 10:29:00 AM EDT. Market Open.
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 1,382,936 | 14 |
| Sales | 258,574 | 4 |
| Net Shares Purchased (Sold) | 1,124,362 | 18 |
| Total Insider Shares Held | 20.61M | -- |
| % Net Shares Purchased (Sold) | 5.80% | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| LI DEAN Y Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Apr 1, 2025 |
| DAR ZAVAIN Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Apr 1, 2025 |
| GIBSON CHRISTOPHER C Chief Executive Officer | Sale at price 6.04 per share. | Direct | 836,987 | Mar 27, 2025 |
| SUN ELAINE D Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Mar 17, 2025 |
| BUMPUS NAMANDJE N. Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Mar 17, 2025 |
| GIBSON CHRISTOPHER C Chief Executive Officer | Sale at price 6.37 - 6.58 per share. | Direct | 259,000 | Mar 6, 2025 |
| GIBSON CHRISTOPHER C Chief Executive Officer | -- | Direct | -- | Mar 6, 2025 |
| GIBSON CHRISTOPHER C Chief Executive Officer | Sale at price 7.68 - 8.12 per share. | Direct | 316,000 | Feb 6, 2025 |
| GIBSON CHRISTOPHER C Chief Executive Officer | -- | Direct | -- | Feb 6, 2025 |
| TAYLOR BEN R Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 3, 2025 |
| GIBSON CHRISTOPHER C Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 3, 2025 |
| KHAN NAJAT Officer and Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 3, 2025 |
| GIBSON CHRISTOPHER C Chief Executive Officer | Sale at price 7.05 - 7.31 per share. | Direct | 287,200 | Jan 10, 2025 |
| GIBSON CHRISTOPHER C Chief Executive Officer | -- | Direct | -- | Jan 10, 2025 |
| LI DEAN Y Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 2, 2025 |
| BORGESON BLAKE CHARLES Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 2, 2025 |
| DAR ZAVAIN Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 2, 2025 |
| TAYLOR BEN R Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Dec 19, 2024 |
| GIBSON CHRISTOPHER C Chief Executive Officer | Sale at price 7.12 - 7.16 per share. | Direct | 285,600 | Dec 5, 2024 |
| GIBSON CHRISTOPHER C Chief Executive Officer | -- | Direct | -- | Dec 5, 2024 |
| MICHOR FRANZISKA PH.D. Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Nov 20, 2024 |
| GIBSON CHRISTOPHER C Chief Executive Officer | Sale at price 7.35 - 7.74 per share. | Direct | 301,800 | Nov 14, 2024 |
| GIBSON CHRISTOPHER C Chief Executive Officer | -- | Direct | -- | Nov 14, 2024 |
| SECORA MICHAEL Chief Financial Officer | Sale at price 7.64 - 7.66 per share. | Direct | 229,504 | Nov 13, 2024 |
| SECORA MICHAEL Chief Financial Officer | Conversion of Exercise of derivative security at price 2.22 per share. | Direct | 174,825 | Nov 13, 2024 |
| BORGESON BLAKE CHARLES Director | Sale at price 7.64 per share. | Direct | 87,457 | Nov 12, 2024 |
| BORGESON BLAKE CHARLES Director | Sale at price 6.72 per share. | Direct | 76,926 | Oct 29, 2024 |
| MARRIOTT TINA LARSON President | Sale at price 6.31 per share. | Direct | 37,855 | Oct 24, 2024 |
| MARRIOTT TINA LARSON President | Conversion of Exercise of derivative security at price 1.06 per share. | Direct | 6,360 | Oct 24, 2024 |
| BORGESON BLAKE CHARLES Director | Sale at price 6.67 per share. | Direct | 76,326 | Oct 15, 2024 |
| SECORA MICHAEL Chief Financial Officer | Sale at price 6.32 - 6.36 per share. | Direct | 190,131 | Oct 9, 2024 |
| SECORA MICHAEL Chief Financial Officer | Conversion of Exercise of derivative security at price 2.22 per share. | Direct | 174,825 | Oct 9, 2024 |
| GIBSON CHRISTOPHER C Chief Executive Officer | Sale at price 6.08 - 6.16 per share. | Direct | 244,800 | Oct 3, 2024 |
| GIBSON CHRISTOPHER C Chief Executive Officer | -- | Direct | -- | Oct 3, 2024 |
| LI DEAN Y Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Oct 1, 2024 |
| BORGESON BLAKE CHARLES Director | Sale at price 6.22 per share. | Direct | 71,150 | Oct 1, 2024 |
| BORGESON BLAKE CHARLES Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Oct 1, 2024 |
| DAR ZAVAIN Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Oct 1, 2024 |
| MARRIOTT TINA LARSON President | Sale at price 7.00 per share. | Direct | 42,005 | Sep 26, 2024 |
| MARRIOTT TINA LARSON President | Conversion of Exercise of derivative security at price 1.06 per share. | Direct | 6,360 | Sep 26, 2024 |
| BORGESON BLAKE CHARLES Director | Sale at price 6.84 per share. | Direct | 78,333 | Sep 17, 2024 |
| SECORA MICHAEL Chief Financial Officer | Sale at price 6.17 - 6.32 per share. | Direct | 187,228 | Sep 11, 2024 |
| SECORA MICHAEL Chief Financial Officer | Conversion of Exercise of derivative security at price 2.22 per share. | Direct | 174,825 | Sep 11, 2024 |
| GIBSON CHRISTOPHER C Chief Executive Officer | Sale at price 6.04 - 6.14 per share. | Direct | 243,600 | Sep 5, 2024 |
| GIBSON CHRISTOPHER C Chief Executive Officer | -- | Direct | -- | Sep 5, 2024 |
| BORGESON BLAKE CHARLES Director | Sale at price 6.27 per share. | Direct | 71,718 | Sep 3, 2024 |
| GIBSON CHRISTOPHER C Chief Executive Officer | Conversion of Exercise of derivative security at price 2.48 per share. | Direct | 12,400 | Aug 30, 2024 |
| GIBSON CHRISTOPHER C Chief Executive Officer | Conversion of Exercise of derivative security at price 2.48 per share. | Direct | 12,400 | Aug 29, 2024 |
| MARRIOTT TINA LARSON President | Sale at price 7.56 per share. | Direct | 45,376 | Aug 29, 2024 |
| MARRIOTT TINA LARSON President | Conversion of Exercise of derivative security at price 1.06 per share. | Direct | 6,360 | Aug 29, 2024 |
Related Tickers
PHAT Phathom Pharmaceuticals, Inc.
9.22
+4.38%
KLTO Klotho Neurosciences, Inc.
3.3104
+81.89%
LYEL Lyell Immunopharma, Inc.
12.73
+2.08%
LYRA Lyra Therapeutics, Inc.
18.50
+0.43%
CRSP CRISPR Therapeutics AG
44.59
+5.94%
EYEN Eyenovia, Inc.
4.2912
-0.67%
CLRB Cellectar Biosciences, Inc.
0.3773
+6.28%
LIMN Liminatus Pharma, Inc.
24.45
-5.96%
SMMT Summit Therapeutics Inc.
22.63
+4.96%
HOTH Hoth Therapeutics, Inc.
1.2200
+2.52%